The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
Esiloc was launched at the biggest doctor engagement webinar involving more than 12,000 doctors across the country
These were the findings of the Post Marketing Surveillance (PMS), study of Favipiravir (FabiFlu) on over 1000 patients
The study was conducted in patients with mild to moderate COVID-19
Subscribe To Our Newsletter & Stay Updated
